Articles written by Spruce Biosciences - Benzinga

Spruce Biosciences Appoints Renowned Drug Developer Kirk Ways, M.D., Ph.D. to Board of Directors

Dr. Ways’ Expertise in Late-Stage Clinical Development in Therapeutics Areas of High Unmet Medical Meet Supports Spruce’s Goal to Expand Portfolio of Indications for Tildacerfont

Sponsored

Spruce Biosciences Announces Publication of Phase 2 Results for Tildacerfont in Journal of Clinical Endocrinology and Metabolism

Tildacerfont was Evaluated in Two Phase 2 Open-Label Studies in Adults with Classic Congenital Adrenal Hyperplasia (CAH) Data Demonstrated Normalization or Trend to Normalization in Key Hormone Biomarkers Tildacerfont is First CRF1 Receptor Antagonist Studied Beyond 2 Weeks in CA

Sponsored